UroGen Pharma
URGN
172 hedge funds and large institutions have $835M invested in UroGen Pharma in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 52 increasing their positions, 47 reducing their positions, and 25 closing their positions.
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
11% more call options, than puts
Call options by funds: $4.26M | Put options by funds: $3.83M
11% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 47
3% more funds holding
Funds holding: 167 → 172 (+5)
1.97% more ownership
Funds ownership: 93.38% → 95.36% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
18% less capital invested
Capital invested by funds: $1.02B → $835M (-$189M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$52.5M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$45.1M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$23.3M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$11.6M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$55.5M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$14.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.42M |
| 5 |
SCM
Superstring Capital Management
New York
|
-$6.64M |
URGN Hedge Fund Activity: Q1 2026 in Review
172 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2026, worth a combined $835M — down 18% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new URGN positions and 25 closed out — a net gain of 8 holders — while 52 added to existing stakes and 47 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $52.5M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $55.5M.
- 172 institutional investors held UroGen Pharma (URGN) as of Q1 2026, up from 167 in Q4 2025.
- Funds reported $835M of UroGen Pharma stock for Q1 2026, down 18% quarter-over-quarter.
- 33 funds opened new UroGen Pharma positions in Q1 2026 and 25 closed out, a net change of +8 holders.
- The largest UroGen Pharma buyer in Q1 2026 was Toronto Dominion Bank, an estimated $52.5M added.
- The largest UroGen Pharma seller in Q1 2026 was Paradigm Biocapital Advisors, an estimated $55.5M sold.
Based on aggregated 13F filings for Q1 2026.